Combo Rx Plus Stem-Cell Tx Ups PFS in Multiple Myeloma

Share this content:
Combo Rx Plus Stem-Cell Tx Ups PFS in Multiple Myeloma
Combo Rx Plus Stem-Cell Tx Ups PFS in Multiple Myeloma

FRIDAY, April 7, 2017 (HealthDay News) -- Combination therapy with lenalidomide, bortezomib, and dexamethasone (RVD) plus stem-cell transplantation is associated with longer progression-free survival than RVD alone for adults with multiple myeloma, according to a study published in the April 6 issue of the New England Journal of Medicine.

Michel Attal, M.D., from the Institut Universitaire du Cancer de Toulouse-Oncopole in France, and colleagues randomized patients with multiple myeloma to receive induction therapy with three cycles of RVD, then consolidation therapy with either five additional cycles of RVD (350 patients) or high-dose melphalan plus stem-cell transplantation followed by two additional RVD cycles (350 patients).

The researchers found that the group that underwent transplantation had significantly longer median progression-free survival compared to the group that received RVD alone (50 versus 36 months; adjusted hazard ratio for disease progression or death, 0.65; P < 0.001). This benefit was seen for all patient subgroups. The transplantation group had a higher percentage of patients with a complete response (59 versus 48 percent; P = 0.03) and a higher percentage of patients in whom minimal residual disease was not detected (79 versus 65 percent; P < 0.001). At four years there was no significant difference between the groups in overall survival (81 and 82 percent, respectively; P = 0.87).

"RVD therapy plus transplantation was associated with significantly longer progression-free survival than RVD therapy alone, but overall survival did not differ significantly between the two approaches," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Celgene, which funded the study.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Amount of Opioids Prescribed After Hospital Discharge Varies

Amount of Opioids Prescribed After Hospital Discharge Varies

45.6 percent of patients using no opioids 24 hours predischarge were prescribed opioids at discharge

Observation Care Cost Saving in Commercially-Insured Patients

Observation Care Cost Saving in Commercially-Insured Patients

Total, out-of-pocket spending considerably lower for observation care; both increased from '09 to '13

Disrupted Sleep Linked to Increased Amyloid- Production

Disrupted Sleep Linked to Increased Amyloid-&#946; Production

Sleep deprivation tied to increased overnight amyloid-β-38, -40, -42 levels by 25 to 30 percent

is free, fast, and customized just for you!

Already a member?

Sign In Now »